During the past decade, Texas Center for Drug Development, Inc. conducted 51 clinical trials. In the 10-year time frame, 51 clinical trials started and 46 clinical trials were completed, i.e. on average, 90.2% percent of trials that started reached the finish line to date. In the past 5 years, 34 clinical trials started and 20 clinical trials were completed. i.e. 58.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Center for Drug Development, Inc." #1 sponsor was "Pfizer" with 33 trials, followed by "AstraZeneca" with 6 trials sponsored, "BioNTech SE" with 5 trials sponsored, "Shire" with 5 trials sponsored and "ModernaTX, Inc." with 5 trials sponsored. Other sponsors include 23 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Center for Drug Development, Inc." #1 collaborator was "Pfizer" with 5 trials as a collaborator, "Bristol-Myers Squibb" with 3 trials as a collaborator, "Alder Biopharmaceuticals, Inc." with 1 trials as a collaborator, "Clinical Research Management, Inc." with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Texas Center for Drug Development, Inc." are "Migraine" (7 trials), "Type 2 Diabetes Mellitus" (7 trials), "Binge Eating Disorder" (6 trials), "COVID-19" (5 trials) and "SARS-CoV-2 Infection" (5 trials). Many other conditions were trialed in "Texas Center for Drug Development, Inc." in a lesser frequency.

Most popular intervention types in "Texas Center for Drug Development, Inc." are "Drug" (46 trials), "Biological" (36 trials), "Other" (12 trials), "Behavioral" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (50 trials), "BNT162b2" (4 trials), "Lisdexamfetamine dimesylate" (4 trials), "Rimegepant" (4 trials) and "Dapagliflozin" (3 trials). Other intervention names were less common.

The vast majority of trials in "Texas Center for Drug Development, Inc." are 74 trials for "All" genders, 6 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Center for Drug Development, Inc.". undefined are not yet recruiting, 6 are recruiting, 12 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 59 completed trials in Texas Center for Drug Development, Inc., undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Center for Drug Development, Inc., 3 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 57 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".